We are a team of synthetic chemists and process scientists dedicated to enabling the next generation of complex drug modalities.
Astinova Bio Labs exists to make the most complex and impactful chemistry in drug discovery accessible to biotechs, pharmaceutical companies, and academic drug discovery groups worldwide.
We believe that the gap between exciting biological hypotheses and testable chemical matter is often a chemistry problem — one that requires specialized expertise, dedicated resources, and a true partnership mindset.
By building an integrated CRO-CDMO platform with deep advanced modality expertise, we help our partners move faster, with better compounds, from idea to clinical candidate.
"We built Astinova because complex chemistry expertise shouldn't be a bottleneck in drug discovery. Every program we support brings the scientific community one step closer to new medicines."
The drug discovery landscape has undergone a revolution. Targeted protein degradation, ADC chemistry, macrocyclic scaffolds — these modalities require synthetic expertise that most organizations simply cannot afford to build in-house. Meanwhile, the CRO landscape was fragmented: companies offering discovery services couldn't scale to manufacturing, and CDMOs lacked the deep chemistry know-how for complex modalities.
Astinova was founded by scientists with deep backgrounds in medicinal chemistry, total synthesis, and process chemistry — individuals who had worked across the drug discovery value chain and understood both the scientific challenges and the operational demands of CRO-CDMO partnerships. We assembled a team that could handle the full complexity of modern drug discovery chemistry.
We designed Astinova from the ground up as an integrated platform — not a discovery shop that added manufacturing as an afterthought, and not a manufacturing facility that dabbles in chemistry. Every system, workflow, and team structure was designed to support seamless transitions from hit identification through clinical supply manufacturing, with advanced modality expertise at the center of everything we do.
Four principles that guide every project, every partnership, every day.
We hold ourselves to the highest scientific standards. Our chemistry must be correct, our data must be reliable, and our interpretations must be honest — even when the data is inconvenient.
We see ourselves as an extension of your team, not a vendor. We engage deeply with the science, communicate proactively, and make decisions with your program's success as our priority.
We embrace the most challenging chemistry problems as opportunities. Novel molecules require novel thinking, and we constantly push our synthetic repertoire to address tomorrow's modalities today.
Compound quality is non-negotiable. From full spectroscopic characterization to rigorous purity standards, every compound we deliver meets or exceeds the specifications your program requires.
Experienced scientists with deep expertise across medicinal chemistry, process chemistry, and drug development.
Ph.D. Organic Chemistry
Synthetic chemist with extensive experience in medicinal chemistry, PROTAC design, and leading discovery-stage chemistry programs at major pharmaceutical organizations.
15+ years in drug discovery chemistry
Ph.D. Medicinal Chemistry
Expert in advanced modality chemistry including PROTAC synthesis, ADC component design, and asymmetric synthesis. Led multiple clinical candidate programs from hit identification to IND-enabling studies.
12+ years in medicinal chemistry
Ph.D. Process Chemistry
Process chemistry specialist with deep expertise in route scouting, process optimization, scale-up, and CMC documentation for complex API programs. Experience with GMP manufacturing environments.
10+ years in process development
Our team includes additional synthetic chemists, analytical scientists, and project managers — all dedicated to your program's success.
Discuss your program with our team →Astinova operates under quality management principles aligned with international regulatory standards.
Operations and documentation aligned with ICH Q7 (GMP API), Q3A/B (impurities), and Q2 (analytical validation) guidelines.
All client programs are protected by comprehensive Non-Disclosure Agreements signed prior to any exchange of scientific information.
Documented quality management system covering SOPs, change control, deviation management, and CAPA processes.
All IP generated on client programs belongs to the client. We maintain strict information barriers between client programs.
Rigorous environmental, health, and safety protocols including hazard assessments for all chemical processes and materials.
Process and analytical documentation structured to support IND/CTA submissions and subsequent regulatory review during clinical development.
Let's discuss your chemistry challenges. Our team will respond within 48 hours.
Get in Touch